Skip to content
value.today

OncoResponse Inc

🇺🇸 Seattle, Washington, USABiotechnologyFounded 2015
Total raised
$109 M
5 rounds on record
Latest round
$6 M
Apr 2025
First round on record
Sep 2015
Today
Private
No later event on record

Funding rounds

5 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of OncoResponse Inc
MonthRaisedRaiseSizeInvestorsSoldFiling
Apr 2025$6 MNo. 5$2 to $10 million

OncoResponse Inc: Raise no. 5, Apr 2025

Investors in this round

9 investors had bought by the notice of May 6, 2025: 9 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$6 M (amount offered: indefinite)
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Alice J. Bexon · Executive Officer
  • Chris D. Russell · Executive Officer
  • Clifford J. Stocks · Director, Executive Officer
  • Kamal D. Puri · Executive Officer
  • Carol D. Gallagher · Director
  • John A. McKearn · Director
  • Roberto D. De Ponti · Director
  • Sean A. McCarthy · Director
  • Steven D. Gillis · Director
  • Wende D. Hutton · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Clifford J. Stocks, Chief Executive Officer. Source: SEC Form D, newest notice filed May 6, 2025. Read the notice at the SEC.

equity, optionsSEC
May 2023$14 MNo. 4$10 to $50 million

OncoResponse Inc: Raise no. 4, May 2023

Investors in this round

13 investors had bought by the notice of May 12, 2023: 13 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$14 M of $40 M offered; $26 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
$4,800,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Christopher A. Russell · Executive Officer
  • Clifford J. Stocks · Executive Officer, Director
  • Kamal D. Puri · Executive Officer
  • Robert J. Lechleider · Executive Officer
  • John A. McKearn · Director
  • Roberto A. DePonti · Director
  • Sean A. McCarthy · Director
  • Steven A. Gillis · Director
  • Ted A. Koutouzis · Director
  • Wende A. Hutton · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “The amount reflects payment of accrued and unpaid bonuses from periods prior to the offering and anticipated salary to the listed executive officers and potential bonus payments for the following 24-month period.”

Signed by Clifford J. Stocks, Chief Executive Officer. Source: SEC Form D, newest notice filed May 12, 2023. Read the notice at the SEC.

equitySEC
Mar 2021$41 MNo. 3$10 to $50 million

OncoResponse Inc: Raise no. 3, Mar 2021

Investors in this round

14 investors had bought by the notice of Mar 31, 2021: 14 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$41 M of $60 M offered; $19 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
$1,400,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Bob Joseph Lechleider · Executive Officer
  • Clifford Stocks · Executive Officer, Director
  • Kamal Joseph Puri · Executive Officer
  • Daguang Joseph Wang · Director
  • John McKearn · Director
  • Patrick Joseph Hojlo · Director
  • Roberto DePonti · Director
  • Steven Gillis · Director
  • Ted Koutouzis · Director
  • Wende Hutton · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “The amount reflects payment of accrued and unpaid bonuses from periods prior to the offering and anticipated salary to the listed executive officers and potential bonus payments for the following 24-month period.”

Signed by Clifford J. Stocks, Chief Executive Officer. Source: SEC Form D, newest notice filed Mar 31, 2021. Read the notice at the SEC.

equitySEC
Aug 2018$19 MNo. 2$10 to $50 million

OncoResponse Inc: Raise no. 2, Aug 2018

Investors in this round

12 investors had bought by the notice of Sep 6, 2018: 12 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$19 M of $40 M offered; $21 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
$1,200,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Clifford Stocks · Executive Officer, Director
  • Andrew Perlman · Director
  • John McKearn · Director
  • Nathan Jorgensen · Director
  • Roberto DePonti · Director
  • Steven Gillis · Director
  • Wende Hutton · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “The amount reflects payments of accrued and unpaid bonuses from periods prior to the offering and anticipated salary to the listed executive officers and potential bonus payments for the following 24-month period.”

Signed by Clifford J. Stocks, Chief Executive Officer. Source: SEC Form D, newest notice filed Sep 6, 2018. Read the notice at the SEC.

equitySEC
Sep 2015$30 MNo. 1$10 to $50 million

OncoResponse Inc: Raise no. 1, Sep 2015

Investors in this round

12 investors had bought by the notice of Mar 23, 2017: 12 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$30 M of $34 M offered; $5 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Clifford Stocks · Executive Officer, Director
  • Russ Hawkinson · Executive Officer
  • Alan Ginsberg · Director
  • Andrew Perlman · Director
  • Roberto De Ponti · Director
  • Steve Gillis · Director
  • Wende Hutton · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Russ Hawkinson, Chief Financial Officer. Source: SEC Form D and 2 amendments, newest notice filed Mar 23, 2017. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • OncoResponse Inc chose not to state its revenue in its newest notice of a funding round (May 2025).

    SEC Form D · May 2025

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · May 2025

That is all the official record says: OncoResponse Inc has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of OncoResponse Inc is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 5 rounds above had up to 14 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by OncoResponse Inc
NameRoleNamed in
Alice J. BexonExecutive officerMay 2025
Chris D. RussellExecutive officerMay 2025
Clifford J. StocksExecutive officerMay 2025
Kamal D. PuriExecutive officerMay 2025
Christopher A. RussellExecutive officerMay 2023
Robert J. LechleiderExecutive officerMay 2023
Bob Joseph LechleiderExecutive officerMar 2021
Clifford StocksExecutive officerMar 2021
Kamal Joseph PuriExecutive officerMar 2021
Russ HawkinsonExecutive officerMar 2017
Kristine SwiderekExecutive officerMay 2016
Carol D. GallagherDirectorMay 2025
Clifford J. StocksDirectorMay 2025
John A. McKearnDirectorMay 2025
Roberto D. De PontiDirectorMay 2025
Sean A. McCarthyDirectorMay 2025
Steven D. GillisDirectorMay 2025
Wende D. HuttonDirectorMay 2025
Roberto A. DePontiDirectorMay 2023
Steven A. GillisDirectorMay 2023
Ted A. KoutouzisDirectorMay 2023
Wende A. HuttonDirectorMay 2023
Clifford StocksDirectorMar 2021
Daguang Joseph WangDirectorMar 2021
John McKearnDirectorMar 2021
Patrick Joseph HojloDirectorMar 2021
Roberto DePontiDirectorMar 2021
Steven GillisDirectorMar 2021
Ted KoutouzisDirectorMar 2021
Wende HuttonDirectorMar 2021
Andrew PerlmanDirectorSep 2018
Nathan JorgensenDirectorSep 2018
Alan GinsbergDirectorMar 2017
Roberto De PontiDirectorMar 2017
Steve GillisDirectorMar 2017
Geeta VemuriDirectorMay 2016